Maraviroc in the treatment of HIV infection

Drug Design, Development and Therapy

Volumn , Issue 2, 2008, Pages 151-161

  Ray, Neelanjana ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

CCR5 inhibitor; Coreceptor usage; Drug resistance; HIV; Maraviroc

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; EFAVIRENZ; HGS 004; IBALIZUMAB; LAMIVUDINE PLUS ZIDOVUDINE; MARAVIROC; MONOCLONAL ANTIBODY; PF 232798; PRO 140; RANTES; RITONAVIR; UNCLASSIFIED DRUG; VICRIVIROC; ZINC FINGER PROTEIN;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CLINICAL TRIAL; COMPETITIVE INHIBITION; DIZZINESS; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG POTENTIATION; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; LIVER TOXICITY; MONOTHERAPY; NAUSEA; NONHUMAN; OPPORTUNISTIC INFECTION; ORTHOSTATIC HYPOTENSION; REVIEW; RHINITIS; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS RESISTANCE;

EID: 77953676028     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/dddt.s3474     Document Type: Review

References (70)

1. Baba M, Miyake H, Wang X, et al. 2007. Isolation and characterization of human immunodeficiency virus type 1 resistant to the small-molecule CCR5 antagonist TAK-652. Antimicrob Agents Chemother, 51:707-715 (Pubitemid 46185293)
2. Biti R, Ffrench R, Young J, et al. 1997. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med, 3:252-253 (Pubitemid 27112898)
3. Brumme ZL, Goodrich J, Mayer HB, et al. 2005. Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis, 192:466-474 (Pubitemid 41023125)
4. Cocchi F, DeVico AL, Garzino-Demo A, et al. 1995. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science, 270:1811-1815 (Pubitemid 3011045)
5. Coffield VM, Jiang Q, Su L. 2003. A genetic approach to inactivating chemokine receptors using a modified viral protein. Nat Biotechnol, 21:1321-1327 (Pubitemid 37356617)
6. Cormier EG, Dragic T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol, 76:8953-8957 (Pubitemid 34864089)
7. De Jong JJ, De Ronde A, Keulen W, et al. 1992. Minimal requirements for the human immunodeficiency virus type 1 V3 domain to support the syncytium-inducing phenotype: analysis by single amino acid substitution. J Virol, 66:6777-6780
8. Dean M, Carrington M, Winkler C, et al. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science, 273:1856-1862
9. Dorr P, Westby M, McFadyen L, et al. 2008. PF-232798, a second generation oral CCR5 antagonist [abstract]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA. Abstract 737.
10. Dragic T, Trkola A, Thompson DA, et al. 2000. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA, 97:5639-5644 (Pubitemid 30313771)
11. Fätkenheuer G, Pozniak A, Johnson M, et al. 2004. Evaluation of dosing frequency and food effect on viral load reduction during short-term monotherapy with UK-427, 857 a novel CCR5 antagonist [abstract]. The XV International AIDS Conference. Bangkok, Thailand. Abstract no. TuPeB4489.
12. Fätkenheuer G, Pozniak AL, Johnson MA, et al. 2005. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med, 11: 1170-1172 (Pubitemid 43093663)
13. Fouchier RA, Brouwer M, Broersen SM, et al. 1995. Simple determination of human immunodeficiency virus type 1 syncytium-inducing V3 genotype by PCR. J Clin Microbiol, 33:906-911
14. Fouchier RA, Groenink M, Kootstra NA, et al. 1992. Phenotype-associated sequence variation in the third variable domain of the human immunodeficiency virus type 1 gp120 molecule. J Virol, 66:3183-3187
15. Glass WG, Lim JK, Cholera R, et al. 2005. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection. J Exp Med, 202:1087-1098 (Pubitemid 41464502)
16. Glass WG, McDermott DH, Lim JK, et al. 2006. CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med, 203:35-40. (Pubitemid 43139642)
17. Gonzalez E, Kulkarni H, Bolivar H, et al. 2005. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science, 307:1434-1440 (Pubitemid 40321934)
18. Gorry PR, Zhang C, Wu S, et al. 2002. Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet, 359:1832-1834 (Pubitemid 34607062)
19. Hardy D, Reynes J, Konourina I, et al. 2008. Efficacy and safety of maraviroc plus optimized background therapy in treatment-experienced patients infected with CCR5-Tropic HIV-1: 48-week combined analysis of the MOTIVATE studies [abstract]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA. Abstract 792.
20. Hartley O, Gaertner H, Wilken J, et al. 2004. Medicinal chemistry applied to a synthetic protein: development of highly potent HIV entry inhibitors. Proc Natl Acad Sci USA, 101:16460-16465 (Pubitemid 39557735)
21. Hartley O, Offord RE. 2005. Engineering chemokines to develop optimized HIV inhibitors. Curr Protein Pept Sci, 6:207-219 (Pubitemid 40812746)
22. Heera J, Saag MS, Ive P, et al. 2008. Virological correlates associated with treatment failure at week 48 in the phase 3 study of maraviroc in treatment-naive patients [abstract]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA. Abstract 40LB.
23. Huang CC, Lam SN, Acharya P, et al. 2007. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science, 317:1930-1934 (Pubitemid 47509439)
24. Huang Y, Paxton WA, Wolinsky SM, et al. 1996. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med, 2:1240-1243 (Pubitemid 26375409)
25. Hunt PW, Harrigan PR, Huang W, et al. 2006. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia. J Infect Dis, 194: 926-930 (Pubitemid 44454078)
26. Jensen MA, Li FS, van't Wout AB, et al. 2003. Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol, 77:13376-13388
27. Kish-Catalone TM, Lu W, Gallo RC, et al. 2006. Preclinical evaluation of synthetic -2 RANTES as a candidate vaginal microbicide to target CCR5. Antimicrob Agents Chemother, 50:1497-1509
28. Koot M, Keet IP, Vos AH, et al. 1993. Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS. Ann Intern Med, 118:681-688 (Pubitemid 23118038)
29. Koot M, van Leeuwen R, de Goede RE, et al. 1999. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis, 179:254-258 (Pubitemid 29028366)
30. Korber BT, Farber RM, Wolpert DH, et al. 1993. Covariation of mutations in the V3 loop of human immunodeficiency virus type 1 envelope protein: an information theoretic analysis. Proc Natl Acad Sci USA, 90:7176-7180
31. Kuhmann SE, Pugach P, Kunstman KJ, et al. 2004. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol, 78:2790-2807 (Pubitemid 38314338)
32. Lalezari J, Yadavalli GK, Para M, et al. 2008. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis, 197:721-727 (Pubitemid 351364473)
33. Lalezari JP, Goodrich J, DeJesus E, et al. 2007. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1: 24 week results from a phase 2b/3 study in the US and Canada [abstract]. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles. Abstract 104bLB.
34. Liu R, Paxton WA, Choe S, et al. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell, 86:367-377 (Pubitemid 26272077)
35. Lusso P. 2006. HIV and the chemokine system: 10 years later. Embo J, 25:447-456
36. Mani M, Kandavelou K, Dy FJ, et al. 2005. Design, engineering, and characterization of zinc finger nucleases. Biochem Biophys Res Commun, 335:447-457 (Pubitemid 41140243)
37. Marozsan AJ, Kuhmann SE, Morgan T, et al. 2005. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology, 338:182-199 (Pubitemid 40835936)
38. Meanwell NA, Kadow JF 2007. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr Opin Investig Drugs, 8:669-681
39. Melby T, Despirito M, Demasi R, et al. 2006. HIV-1 coreceptor use in triple-class treatment-experienced patients: baseline prevalence, correlates, and relationship to enfuvirtide response. J Infect Dis, 194:238-246 (Pubitemid 44087196)
40. Michael NL, Chang G, Louie LG, et al. 1997. The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression. Nat Med, 3:338-340 (Pubitemid 27112934)
41. Michael NL, Nelson JA, KewalRamani VN, et al. 1998. Exclusive and persistent use of the entry coreceptor CXCR4 by human immunodeficiency virus type 1 from a subject homozygous for CCR5 delta 32. J Virol, 72:6040-6047
42. Moore JP. 2005. Topical microbicides become topical. N Engl J Med, 352:298-300.
43. Moyle GJ, Wildfire A, Mandalia S, et al. 2005. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis, 191:866-872 (Pubitemid 40349800)
44. Murga JD, Franti M, Pevear DC, et al. 2006. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother, 50:3289-3296 (Pubitemid 44527500)
45. Nelson M, Fatkenheuer G, Konourina I, et al. 2007. Efficacy and safety of maraviroc plus optimized background therapy in viremic ART-experienced patients infected with CCR5-tropic HIV-1 in Europe, Australia and North America: 24 week results [abstract]. 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles. Abstract 104aLB.
46. O'Brien TR, Winkler C, Dean M, et al. 1997. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet, 349:1219. (Pubitemid 27190047)
47. Ogert RA, Wojcik L, Buontempo C, et al. 2008. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology, 373:387-399
48. Paxton WA, Martin SR, Tse D, et al. 1996. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med, 2: 412-417 (Pubitemid 26191912)
49. Perez E, Wang J, Miller J, et al. 2008. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol, 26:808-816 (Pubitemid 351961450)
50. Progenics PRO 140. Accessed 17 July 2008. URL: http://www.progenics.com/ pro140.cfm.
51. Pugach P, Marozsan AJ, Ketas TJ, et al. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology, 361:212-228 (Pubitemid 46551222)
52. Reeves JD, Han D, Hunt P, et al. 2007. Enhancements to the Trofile HIV coreceptor tropism assay enable improved detection of CXCR4-using subpopulations and earlier detection of CXCR4-using viruses in sequential patient samples [abstract]. 3rd International Workshop on Targeting HIV Entry. Washington, DC. Abstract 11.
53. Rossi JJ, June CH, Kohn DB. 2007. Genetic therapies against HIV. Nat Biotechnol, 25:1444-1454 (Pubitemid 350233141)
54. Saag MS, Ive P, Heera J, et al. 2007. A multicenter, randomized, double-blind, comparative trial of a novel CCR5 antagonist, maraviroc versus efavirenz, both in combination with Combivir (zidovudine [ZDV]/lamivudine [3TC]), for the treatment of antiretroviral naive patients infected with R5 HIV 1: Week 48 results of the MERIT study. 4th International AIDS Society Conference. Sydney, Australia.
55. Samson M, Libert F, Doranz BJ, et al. 1996. Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature, 382:722-725 (Pubitemid 26282179)
56. Seibert C, Ying W, Gavrilov S, et al. 2006. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology, 349:41-54.
57. Shankarappa R, Margolick JB, Gange SJ, et al. 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol, 73:10489-10502
58. Sierra S, Kaiser R, Thielen A, et al. 2007. Genotypic coreceptor analysis. Eur J Med Res, 12:453-462
59. Simmons G, Clapham PR, Picard L, et al. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science, 276:276-279 (Pubitemid 27172690)
60. Theodorou I, Meyer L, Magierowska M, et al. 1997. HIV-1 infection in an individual homozygous for CCR5 delta 32. Seroco Study Group. Lancet, 349:1219-1220
61. Trkola A, Kuhmann SE, Strizki JM, et al. 2002. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA, 99:395-400. (Pubitemid 34060372)
62. Tsamis F, Gavrilov S, Kajumo F, et al. 2003. Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry. J Virol, 77:5201-5208 (Pubitemid 36460934)
63. Watson C, Jenkinson S, Kazmierski W, et al. 2005. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol, 67:1268-1282 (Pubitemid 40410427)
64. Westby M, Smith-Burchnell C, Mori J, et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol, 81:2359-2371 (Pubitemid 46303353)
65. WHO/UNAIDS. 2007. AIDS epidemic update. Accessed date: 17 July 2008. URL: http://www.unaids.org:80/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdArchive/ 2007/.
66. Wilkin TJ, Su Z, Kuritzkes DR, et al. 2007. HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211. Clin Infect Dis, 44:591-595 (Pubitemid 46233265)
67. Wood A and Armour D. 2005. The discovery of the CCR5 receptor antagonist, UK-427,857, a new agent for the treatment of HIV infection and AIDS. Prog Med Chem, 43:239-271
68. Yang AG, Bai X, Huang XF, et al. 1997. Phenotypic knockout of HIV type 1 chemokine coreceptor CCR-5 by intrakines as potential therapeutic approach for HIV-1 infection. Proc Natl Acad Sci USA, 94:11567-11572 (Pubitemid 27451039)
69. Zimmerman PA, Buckler-White A, Alkhatib G, et al. 1997. Inherited resistance to HIV-1 conferred by an inactivating mutation in CC chemokine receptor 5: studies in populations with contrasting clinical phenotypes, defined racial background, and quantified risk. Mol Med, 3:23-36. (Pubitemid 27142522)
70. Zingman B, Suleiman J, DeJesus E, et al. 2008. Vicriviroc, a next generation CCCR5 antagonist, exhibits potent, sustained suppression of viral replication in treatment-experienced adults: VICTOR-E1 48-week results [abstract]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA. Abstract 39LB.